Who are Budesonide + Salmeterol + Azithromycin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/budesonide-salmeterol-azithromycin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Budesonide + Salmeterol + Azithromycin — Competitive Intelligence Brief

Budesonide + Salmeterol + Azithromycin (Budesonide + Salmeterol + Azithromycin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Combination therapy: inhaled corticosteroid + long-acting beta-2 agonist + macrolide antibiotic. Area: Respiratory / Pulmonology.

marketed Combination therapy: inhaled corticosteroid + long-acting beta-2 agonist + macrolide antibiotic Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (salmeterol); bacterial protein synthesis inhibition (azithromycin) Respiratory / Pulmonology Small molecule Live · refreshed every 30 min

Target snapshot

Budesonide + Salmeterol + Azithromycin (Budesonide + Salmeterol + Azithromycin) — National Heart, Lung, and Blood Institute (NHLBI). This combination reduces airway inflammation via corticosteroid and macrolide action while improving bronchodilation through beta-2 agonist stimulation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Budesonide + Salmeterol + Azithromycin TARGET	Budesonide + Salmeterol + Azithromycin	National Heart, Lung, and Blood Institute (NHLBI)	marketed	Combination therapy: inhaled corticosteroid + long-acting beta-2 agonist + macrolide antibiotic	Glucocorticoid receptor (budesonide); beta-2 adrenergic receptor (salmeterol); bacterial protein synthesis inhibition (azithromycin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Combination therapy: inhaled corticosteroid + long-acting beta-2 agonist + macrolide antibiotic class)

National Heart, Lung, and Blood Institute (NHLBI) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Budesonide + Salmeterol + Azithromycin — Competitive Intelligence Brief. https://druglandscape.com/ci/budesonide-salmeterol-azithromycin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab